PREP

What can we help you find?
[[thumbnail_alt_text]]
National Institutes of Health experts discuss optimization of existing strategies for HIV treatment and prevention, as well as the development of new approaches.
 
[[thumbnail_alt_text]]
California has passed SB 159, becoming the first state allowing pharmacists to dispense HIV prevention pills to patients without a doctor’s prescription. Supporters say the legislation will greatly reduce the spread of infection.1

 
[[thumbnail_alt_text]]
TIN Rx is aiming to serve the most vulnerable populations, including LGBTQ patients, homeless patients, and others who may typically face stigma in pharmacies.
 
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
 
[[thumbnail_alt_text]]
The FDA has approved emtricitabine 200 mg and tenofovir alafenamide 25 mg (Descovy, Gilead Sciences Inc.) as a second pre-exposure prophylaxis drug in at-risk adults and adolescents weighing at least 75 Ib.
 
[[thumbnail_alt_text]]
London Mayor Sadiq Khan has called for broader availability of pre-exposure prophylaxis drugs in his welcoming speech at the Fast-Track Cities 2019 conference, where leaders from 300 cities around the world will discuss municipal responses to HIV, tuberculosis, and viral hepatitis.
[[thumbnail_alt_text]]
In recent months, legislation to increase access to pre- and post-exposure prophylaxis (PrEP and PEP) passed in California with a vote of 34-1 in the Senate and a unanimous vote in the Assembly. 
[[thumbnail_alt_text]]
An FDA committee has recommended approval of Gilead’s Descovy to reduce the risk of sexually acquired HIV infection in those at high risk of acquiring the virus.
[[thumbnail_alt_text]]
An FDA committee voted 16 to 2 to recommended emitricitabine 200 mg and tenofovir alafenamide 25 mg tablets (Descovy, Gilead) for a HIV pre-exposure prophylaxis indication.
[[thumbnail_alt_text]]
Pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection in individuals at high risk.
[[thumbnail_alt_text]]
Top news of the day from across the health care landscape.
[[thumbnail_alt_text]]
Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.
+ Load More